Control of invasive pulmonary aspergillosis with oral itraconazole in a bone marrow transplant patient.
Pulmonary aspergillosis following bone marrow transplantation carries a mortality of 94%, irrespective of current treatment. We treated a patient who had acquired aspergillosis some 80 days after allogeneic bone marrow transplantation, with oral itraconazole, 600 mg daily. After initial deterioration, clinical and radiographic resolution occurred during 3 months of therapy despite severe graft-vs.-host and cytomegalovirus disease. Itraconazole should be considered for therapy of pulmonary aspergillosis in this and other immunocompromised settings.
Denning
D W
DW
Department of Medicine, Stanford University Medical Center, CA 94305.
Stepan
D E
DE
Blume
K G
KG
Stevens
D A
DA
D000284:Administration, Oral; D000328:Adult; D000935:Antifungal Agents / Q000627:therapeutic use*; D001228:Aspergillosis / Q000188:drug therapy*; D016026:Bone Marrow Transplantation; D005260:Female; D006086:Graft vs Host Disease / Q000150:complications; D006509:Hepatitis B / Q000150:complications; D006801:Humans; D017964:Itraconazole; D007654:Ketoconazole / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D008172:Lung Diseases, Fungal / Q000188:drug therapy*; D009190:Myelodysplastic Syndromes / Q000628:therapy
D000935:Antifungal Agents; D017964:Itraconazole; D007654:Ketoconazole